Randomized trial · people

Retatrutide: 26.1% fat mass loss at 36 weeks in type 2 diabetes

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this trial, people with type 2 diabetes on the higher retatrutide doses lost a large share of their body fat, and the share of lean mass lost was in line with other obesity treatments.

Kind
Randomized trial
Studied in
People
Number studied
189
Published
2025
Journal
Lancet Diabetes Endocrinol

What they tested

The team tested how much total body fat adults with type 2 diabetes lost over 36 weeks on retatrutide, compared with placebo and with dulaglutide.

How the study was done

A body composition substudy of a randomized, double-blind, placebo-controlled phase 2 trial at 42 US centers, with 189 adults with type 2 diabetes and a BMI of 25-50 kg/m2. Over 36 weeks, they got once-weekly shots of retatrutide (0.5 mg up to 12 mg), dulaglutide 1.5 mg, or placebo (a dummy shot), and body fat was measured by DXA, an X-ray body scan.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Total fat mass fell by 4.9% in the retatrutide 0.5 mg arm, 15.2% in the 4 mg arms, 26.1% in the 8 mg arms and 23.2% in the 12 mg arm, against 2.6% with dulaglutide and 4.5% with placebo. Compared with placebo, the least squares mean change was -10.7 for 4 mg (p=0.0013), -21.6 for 8 mg and -18.7 for 12 mg (both p<0.0001), while the 0.5 mg arm did not differ from placebo (p=0.83). The share of weight lost as lean mass was similar to other obesity treatments. Adverse events were similar across groups, stomach and gut effects were the most common, and no one died.

What it doesn’t show

Of the 189 people in the substudy, only 103 finished treatment with scans at both the start and week 36, and the trial was a 36-week phase 2 study in mostly White adults with type 2 diabetes. It was funded by Eli Lilly and Company.

The paper

Coskun et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025.

The compound

More studies on Retatrutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo